| CABOZANTINIB S-MALATE | None | ||
| 20MG, 80MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). | |||
|
Yes
| |||
| COMETRIQ | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 |
|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||
| *-*** ********** *** ******* ** *** | (*)-****** **** ** *-(*-{[*,*-***(*********) ********-*-**]***}******)-*'-(*-************)************-*,*-************* | ********* *** ********* ********* ********* *** ************** ************ ********** **** ********* | ****** **** ** *-(*-{[*,*-***(*********) ********-*-**]***}******)-*′-(*-************)************-*,*-*************, *** *********** ***** ****** *** *** ********* ** ****** | ****** **** ** *-(*-{[*,*-***(*********) ********-*-**]***}******)- *′-(*-************)************-*,* -*************, *** *********** ***** ******* *** *** ********* ** ****** | ****** **** ** *-(*-{[*,*-***(*********) ********-*-**]***}******)-*′-(*-************)************-*,*-*************, *** *********** ***** ******* *** *** ********* ** ****** | ********* *** ********* ********* ********* *** ************** ************ ********** **** ********* | ********* *** ********* ********* ********* *** ************** ************ ********** **** ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|